Months af­ter a Mer­ck spin­out, Organon con­tin­ues its string of deals with a $954M buy­out pack­age

Five months af­ter eject­ing out of the moth­er ship at Mer­ck, the women’s health ex­perts at Organon have racked up an­oth­er deal, this time buy­ing up a small biotech ad­vanc­ing an ex­per­i­men­tal ther­a­py for en­dometrio­sis.

Organon put out word Thurs­day morn­ing that it bagged Foren­do Phar­ma out of Fin­land to beef up the pipeline. They’re pay­ing $75 mil­lion up­front and shoul­der­ing $9 mil­lion in debt to land the as­set with a hefty $870 mil­lion in mile­stone mon­ey on the ta­ble. Al­to­geth­er the M&A pack­age weighs in at close to a bil­lion dol­lars — pro­vid­ed the drug is suc­cess­ful.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER